Choose Your Country or Region

LY294002

Name: LY294002
Brand: Selleck Chemicals
SKU: S1105
Rating: 5 (1483 reviews)

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

For research use only.

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

CAS No. 154447-36-6

Selleck's LY294002 has been cited by 1483 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Related Compound Libraries

Other PI3K Products

Taselisib (GDC 0032)^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.
Pilaralisib (XL147)^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Download Inhibitor Catalog

PI3K Signaling Pathway Map

Biological Activity

Description

Targets

CK2 ^[5] (Cell-free assay)	p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	DNA-PK ^[6] (Cell-free)
98 nM	0.5 μM	0.57 μM	0.97 μM	1.4 μM

In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1^[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). ^[2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Sf9 cells	NGC3N\|NHfW6ldHnvckBie3OjeR?=			NF[1UIZKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgZo93cW6nIGDJN2sh\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD1zMDFOwG0v	MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUizOVEoRjFyOUm4N\|UyRC:jPh?=
HeLa cells	MnHkRolv\GmwZzDh[oZqdmm2eTDhd5NigQ>?			MXnCbY5lcW6pIHHm[olvcXS7IH\vdkBRUTNva3nuZZNmKGm\|b3zheIVlKG[{b32gTIVN[SClZXzsd{whU2l;NjFOwG0>	M1K2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
HeLa cells	NV3mR2cxTnWwY4Tpc44h[XO\|YYm=			NE\vd4dKdmirYnn0bY9vKG:oIH3UU3IheHKxdHXpckBqe2:uYYTl[EBnem:vIFjlUIEh[2WubIOsJGlEPTB;Mj61JO69VS5?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O\|A9N2F-
HeLa (human carcinoma) cells.	M3;Xb2Z2dmO2aX;uJIF{e2G7			MXXJckB3cXS{bzDpcohq[mm2aX;uJI9nKESQQT3k[ZBmdmSnboSgdJJwfGWrbjDrbY5ie2VqRF7BMXBMMSCocn;tJGhmVGFiKHj1cYFvKGOjcnPpco9u[SliY3XscJMtKEmFNUC9NU41KM7:TT6=	NYnKfZlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OVg5PzBpPkG1OlU5QDdyPD;hQi=>
human PC3 cells	NYDOcWhoWHKxbHnm[ZJifGmxbjDhd5NigQ>?	MlT0NlUh\|ryP	MnzsNVIxKGh?	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjdDCyOUB2VSCjZoTldkAyOjBiaILzJIJ6KE2WVDDhd5NigSC{ZXzheIl3\SC2bzDEUXNQ	MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
human BJ cells	NVyxbmpYTnWwY4Tpc44h[XO\|YYm=	NFvERY8zPSEQvF2=	MVGyJIg>	MkTZRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK\|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd4N{C4OUc,OTZ5NkewPFU9N2F-
human BJ cells	MoPsSpVv[3Srb36gZZN{[Xl?	M{e0VFI2KM7:TR?=	MVuyJIg>	NF7ScXBKdmirYnn0bY9vKG:oIGDJN2she2mpbnHsbY5oKGmwIGDES2Yue3SrbYXsZZRm\CC\|ZYL1cUB{fGG{dnXkJIh2dWGwIFLKJINmdGy\|IITyZY5{\mWldHXkJJdqfGhicHzhd41q\CCHR1\QM3BJKGSxbXHpckBw\iCDa4SgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gVGguTUeIUDDy[YRqe3S{aXL1eIlwdiC2bzDwcIF{dWFibXXtZpJidmViYYSgNlUhfU1idILlZZRm\CB{IHjyd{Bj\W[xcnWgVGRITiClaHHscIVv\2ViYomgZ49v\m:lYXygcYlkem:\|Y3;wfS=>	MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5NkewPFUoRjF4N{[3NFg2RC:jPh?=
mouse mast cells	NGfwWmNHfW6ldHnvckBie3OjeR?=	Mk\lNlAh\|ryP		MVXJcohq[mm2aX;uJI9nKFOFRj3pcoR2[2WmIGDLRk9Cc3RicHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKG2jc4SgZ4VtdHNiYYSgNlAh\|ryP	NV36WVZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O\|g6PzR{PD;hQi=>
THP1 cells	NYLZTYN7TnWwY4Tpc44h[XO\|YYm=			NXPoUphQUW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQh[2inbX;0ZZhqeyCxZjDUTHAyKGOnbHzzMEBKSzVyPUO3JO69VS5?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
mouse Raw264 macrophage	NGD0UJNHfW6ldHnvckBie3OjeR?=			M4XQTmlvcGmkaYTpc44hd2ZiQ{XhMY1m\GmjdHXkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIGLhe\|I3PCCvYXPyc5Bp[WenLDDJR\|UxRTFyIN88UU4>	M1yxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O\|QzLz5zNke4PVc1OjxxYU6=
THP1 cells	NIrrbI9HfW6ldHnvckBie3OjeR?=			NXjWTHg3UW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQhWEuEL1HreEBxcG:\|cHjvdplt[XSrb36gbY4hXEiSMTDj[YxteyxiSVO1NF0yNjZ3IN88UU4>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
THP1 cells	MmH1SpVv[3Srb36gZZN{[Xl?			MVvJcohq[mm2aX;uJI9nKFOFRkGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuNFEh\|ryPLh?=	NULlVnk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O\|g6PzR{PD;hQi=>
human A375 cells	MXTQdo9tcW[ncnH0bY9vKGG\|c3H5		NVy5eGpSPDZiaB?=	NVLJPWlMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIFnfGW{IES2JIhzeyxiSVO1NF05NjRizszNMi=>	NVrTUXpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewOFkzPDhpPkG3NFQ6OjR6PD;hQi=>
HeLa cells	NXHjc\|hsTnWwY4Tpc44h[XO\|YYm=			MoLmTY5pcWKrdHnvckBw\iCDWD23OVA{KGKrbnTpcochfG9icnXjc41jcW6jboSgVIxsOyCneIDy[ZN{\WRiaX6gTIVN[SClZXzsd{BjgSCZZYP0[ZJvKGKub4SsJGlEPT1\|IN88UU4>	NWjySnhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexN\|UzPDhpPkG3NVM2OjR6PD;hQi=>
human SW480 cells	MlW2SpVv[3Srb36gZZN{[Xl?	M4i0OFIxKM7:TR?=	NHPuWmUzPCCq	M332b2Rm[3KnYYPlJIlvKHO3co\peolvKGW6cILld5Nqd25iaX6gbJVu[W5iU2e0PFAh[2WubIOgZZQhOjBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZY5idHm\|aYO=	M3;lOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEeyPVYzLz5zN{S3Nlk3OjxxYU6=
human A375 cells	MUXQdo9tcW[ncnH0bY9vKGG\|c3H5			MnjxTY5pcWKrdHnvckBw\iC\|ZYL1cU1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iQUO3OUBk\WyuczygTWM2OD16LkSg{txONg>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMUezPUc,OTd4MEG3N\|k9N2F-
human A2780 cells	NFO0cmpCeG:ydH;zbZMh[XO\|YYm=	MW[yJO69VQ>?	NXyyfJRLOTJiaB?=	M4SyOWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gZ4l{eGyjdHnuMZJme2m\|dHHueEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDa4SgcIV3\WxiYYSgNkB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqey5?	NIXiU\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFAyQCd-MUe2PFQxOTh:L3G+
human H4 cells	M4HScGZ2dmO2aX;uJIF{e2G7		MUmyJIg>	MXvE[YNz\WG\|ZTDpckBHYV[HLWLGVEshfmW\|aXPs[UBqdnSnboPpeJkheGW{IHPlcIwhcW5iaIXtZY4hUDRiY3XscJMh[W[2ZYKgNkBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?=	NIPOdnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECyOFU5PCd-MUiwNlQ2QDR:L3G+
Sf9 cells	MXvGeY5kfGmxbjDhd5NigQ>?			Mk\ZTY5pcWKrdHnvckBw\iCFS{Kg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF03NjlizszNMi=>	NFT6TXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyNVcyPid-MUizNlE4OTZ:L3G+
rat RBL2H3 cells	MlzBSpVv[3Srb36gZZN{[Xl?			NIrPU\|NKdmirYnn0bY9vKG:oIFGyN\|E5Py2rbnT1Z4VlKGSnZ4LhcpVt[XSrb36gbY4hemG2IGLCUFJJOyClZXzsdy=>	MnXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|Mki3NVYoRjF6M{K4O\|E3RC:jPh?=
human U87MG cells	NHzrcG5HfW6ldHnvckBie3OjeR?=			MVjJcohq[mm2aX;uJI9nKEeVS{OtZoV1[SCrbjDoeY1idiCXOEfNS{Bk\WyuczDifUBGVEmVQTygTWM2OD16LkGg{txONg>?	Mk[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|NEW2NFkoRjF6M{S1OlA6RC:jPh?=
human H460 cells	MoXQSpVv[3Srb36gZZN{[Xl?	NHXJdo0{OCEQvF2=		M1nC[mlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBJPDZyIHPlcIx{KGG\|c3Xzd4VlKGG\|IFHreEBxcG:\|cHjvdplt[XSrb36gZZQhW2W{IES3N{B2eCC2bzCzNEB2VQ>?	MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEG2NFEoRjF6NUCxOlAyRC:jPh?=
human U251HRE cells	NEHqflhHfW6ldHnvckBie3OjeR?=			MWXJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzIHHjeIl3[XSrb36gbY4hcHWvYX6gWVI2OUiURTDj[YxteyCkeTDj[YxtKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZk>	NVKwWpdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NFE3ODFpPkG4OVAyPjBzPD;hQi=>
human 184B5 cells	M{nKWWN6fG:2b4jpZ:Kh[XO\|YYm=			M{\FOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE5PEJ3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1\|OT6zO{DPxE1w	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-468 cells	NVHo[oEzS3m2b4TvfIlkyqCjc4PhfS=>			NVP1PGJ[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:OTBwNDFOwG0v	M2DvRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-468 cells	MkLzR5l1d3SxeHnjxsBie3OjeR?=			Mn7vR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDpckBxemW\|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO\|YYmsJGdKPTB;OD6yJO69VS5?	M4HPUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MDA-MB-231 cells	MlPTR5l1d3SxeHnjxsBie3OjeR?=			MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME22MlcyKM7:TT6=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-468 cells	M3v5cmN6fG:2b4jpZ:Kh[XO\|YYm=			MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy\|IHnuJJBz\XOnbnPlJI9nKDJyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3Ojef-8kEBKSzVyPUSuO\|Yh\|ryPLh?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-231 cells	NYrrfldpS3m2b4TvfIlkyqCjc4PhfS=>			MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD12LkO1JO69VS5?	NWjkRVlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells	MkjmR5l1d3SxeHnjxsBie3OjeR?=			MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHnuJJBz\XOnbnPlJI9nKDJyIN88UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO\|YYmsJGdKRTNwM{Kg{txONg>?	M3;VZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells	MojnR5l1d3SxeHnjxsBie3OjeR?=			Ml3CR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJQVMvOTZizszNMi=>	NHSzUFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MCF7 cells	NETFXFZEgXSxdH;4bYPDqGG\|c3H5			NYrBV282S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCrbjDwdoV{\W6lZTDv[kAyOCC3TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oy5yODFOwG0v	NVPiSGx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells	M2PqSWN6fG:2b4jpZ:Kh[XO\|YYm=			M2HidWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNlAh\|ryPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0zNjZ\|IN88UU4>	NIj5TGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
Sf21 cells	NX\iUI5GTnWwY4Tpc44h[XO\|YYm=			MXrJcohq[mm2aX;uJI9nKG2xdYPlJJJm[2:vYnnuZY51KFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhW2Z{MTDj[YxteyxiSVO1NF0xNjVizszNMi=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEK2PUc,OTl5NEiyOlk9N2F-
Sf9 cells	NFPaVFdndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl?			MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHL5JIZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>?	NFjjVIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGyNVY{OSd-MkGxNlE3OzF:L3G+
Sf9 cells	NIHYc2dHdHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl?			NULUb2FrUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO\|YYmsJGlEPTB;MD61OUDPxE1w	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N\|E9N2F-
human IGROV1 cells	M1rscWZ2dmO2aX;uJIF{e2G7		MVSyOEBp	MnjrR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDC1JIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl?	MkS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells	NEnsemxHfW6ldHnvckBie3OjeR?=		NVHCW5dSOjRiaB?=	MYnD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEGg[o9t\CCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>?	NEH2bmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human IGROV1 cells	MU\GeY5kfGmxbjDhd5NigQ>?		NX7wTXFtOjRxNEigbC=>	M2XzXmlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSVfSU3YyKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHP5Z4xqdiCGMTDs[ZZmdCCjdDCxJJRwKDVidHnt[ZMhUUN3MDDh[pRmeiB{NDD0c{A1QCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NIrjXmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human IGROV1 cells	MkHXSpVv[3Srb36gZZN{[Xl?		MnTRNlQwPDhiaB?=	MlK3TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MkDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human HCT116 cells	MYjDfZRwfG:6aXRCpIF{e2G7		NGXETnc4OiCq	NHXUb4REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02Pi5yMTFOwG0v	NFS0TVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0OVI2OCd-MkG5OFUzPTB:L3G+
human KB cells	NFu1[XNEgXSxdH;4bYPDqGG\|c3H5		NW[1cWtiPzJiaB?=	M{TT[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;NESuO\|Yh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2NUK1NEc,OjF7NEWyOVA9N2F-
HUVEC	NETQZmpHfW6ldHnvckBie3OjeR?=	Mo\aNVAuOjVizszN	NFrxSZc{OCCvaX6=	M32yb2lvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDoeY1idiCLQ1HNMVEheHKxbX;0[ZIh[WO2aY\peJkh\XiycnXzd4VlKGmwIFjVWmVEKGG\|c3Xzd4VlKGG\|IHLleIEu\2GuYXP0c5Nq\GG\|ZTDhZ5Rqfmm2eTDheEAyOCC2bzCyOUB2VSCycnX0doVifGWmIH\vdkA{OCCvaX7zJIJm\m:{ZTDUUmZidHCqYTDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	NVLaNYVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlY1OTBpPkKyNFI3PDFyPD;hQi=>
HUVEC	NYDQc2JrTnWwY4Tpc44h[XO\|YYm=	MX2xNE0zPSEQvF2=	NUPjSWg6OTZiaB?=	M2r0bWlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK\|IHL5JHJVNVCFUjDhcoFtgXOrcx?=	NUnQTpdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlY1OTBpPkKyNFI3PDFyPD;hQi=>
human HCT116 cells	NHu3cGJHfW6ldHnvckBie3OjeR?=	NYrDPFMzOTBizszN		MormTY5pcWKrdHnvckBw\iCDa4Sg[ZhxemW\|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=>	M13EdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO\|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells	NFHHNG9HfW6ldHnvckBie3OjeR?=	M{[3WFExKM7:TR?=		MoLCTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells	MomySpVv[3Srb36gZZN{[Xl?	NXWxUlhJOTBizszN		M1vIR2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGFsfCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJIF1KDFyIIXNJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells	M4\uO2Z2dmO2aX;uJIF{e2G7	NGXYTYYyOCEQvF2=	NFnoUlUyOCCvaX6=	MX;Jcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyC3c3nu[{BcOzKSXVHUVEBifCBzMDD1UUBi\nSncjCxNEBucW6\|	NX7MdIhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells	MYPGeY5kfGmxbjDhd5NigQ>?	M4TRbVExKM7:TR?=	M{DrSVExKG2rbh?=	MnnvTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJJV{cW6pIGuzNnBeSVSSIHH0JFExKHWPIHHmeIVzKDFyIH3pcpM>	NVzm[I9KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells	M3Lp[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXG0PEBp	MoPRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJHBKO0ujbIDoZUBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPU[uO{DPxE1w	M4nR[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO\|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells	NVfDd2lDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MknJOFghcA>?	M1vvPWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2u	M{XIZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO\|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells	NFPqTXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmHZOFghcA>?	NYHOT5BXT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;NT6zJO69VQ>?	NHXjWW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human A549 cells	M2ryWGN6fG:2b4jpZ:Kh[XO\|YYm=		NFy0VZY4OiCq	NWqxfGhMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6	M3Gx[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
human PC3 cells	NYTSUWZWS3m2b4TvfIlkyqCjc4PhfS=>		MVO3NkBp	MlzoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;NkGuN\|Uh\|ryPLh?=	NWfacHI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFA5PTFpPkKyOFgxQDVzPD;hQi=>
human HL60 cells	NIGxZY9EgXSxdH;4bYPDqGG\|c3H5		MkDjO\|IhcA>?	MlHRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUmuPVQh\|ryPLh?=	M3;wXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
Sf21 cells	M{juUmZ2dmO2aX;uJIF{e2G7			NVP6NIpzUW6qaXLpeIlwdiCxZjDtc5V{\SC5aXzkJJR6eGViUFmzT4FteGijIHX4dJJme3OnZDDpckBU\jJzIHPlcIx{KGOxLXX4dJJme3OrbnegUk11\XKvaX7hcEBJcXNvdHHn[4VlKGi3bXHuJJA5PWFidYPpcochVC2jbIDoZU1xcG:\|cHjheIllgWyrbn;zbZRwdCC\|dXLzeJJifGViYomgWGxEKGKjc3XkJJBpd3OyaH;yJIlu[WerbnesJGlEPTB;MD61JO69VQ>?	NVHsV3dkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
HEK293 cells	NVnXPIJzTnWwY4Tpc44h[XO\|YYm=		NFTMfHIyNjViaB?=	MWTEbZNxdGGlZX3lcpQhd2ZiW{PIYWxUTCCocn;tJIh2dWGwIEXIWFYhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{Bi\nSncjCxMlUhcHK\|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5o	NUfyRZF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1N\|cyPTNpPkKyOVM4OTV\|PD;hQi=>
human H1299 cells	NFrac\|NHfW6ldHnvckBie3OjeR?=	MWKwMlEuOzBizszN	NXSwNJlIOjRiaB?=	NVLCcZptUW6mdXP0bY9vKG:oIFrOT{1u\WSrYYTl[EBEUE:SIHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NXXnd5ZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells	NHHofWdHfW6ldHnvckBie3OjeR?=	MXuwMlEuOzBizszN	M3fFWFI1KGh?	M1LrXGlv\HWldHnvckBw\iCGUkWg[ZhxemW\|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NYjSdVVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells	MUDGeY5kfGmxbjDhd5NigQ>?	MWWwMlEuOzBizszN	M{fwfVI1KGh?	NHLIUYRFd3ewIILl[5Vt[XSrb36gc4Yh[0mDUEKg[ZhxemW\|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kAyODBidXevcYwhXFKDSVygZY5lKFCLM1ugbY5pcWKrdH;yJGx[Ojl2MECy	MnLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells	NYjicW1JTnWwY4Tpc44h[XO\|YYm=	MUewMlEuOzBizszN	MkXrNlQhcA>?	M3KzN2Rwf25icnXneYxifGmxbjDv[kBkUUGSMjDlfJBz\XO\|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB\|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
MDA-MB-231 cells	M1u0emNmdGxiaX72ZZNqd25iYYPzZZk>		NGTnZVEzPCCq	M1rqWmlvcGmkaYTpc44hd2ZiZYDpeIhmdGmjbDDndo94fGhiZnHjeI9zNWmwZIXj[YQh[2WubDDtbYdz[XSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDwdoUucW6ldXLheIVlKG[xcjCyOEBpenNiYomgZ4VtdCCrbo\hd4lwdiCjc4PhfUwhUUN3ME2wMlM5KM7:TT6=	M{\Ie\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEC0NVA5Lz5{MkiwOFExQDxxYU6=
human LNCAP cells	M2HhWmZ2dmO2aX;uJIF{e2G7	MmraNE4yNTNyIN88US=>	NWjndJBzOjRiaB?=	NEnRPWxFd3ewcnXneYxifGmxbjDv[kB{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHj1cYFvKEyQQ1HQJINmdGy\|IHH0JFAvOSC2bzCzNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|MkOxOkc,OjJ6M{KzNVY9N2F-
human LNCAP cells	M{LTXGZ2dmO2aX;uJIF{e2G7	M2\yb\|AvOS1\|MDFOwG0>	NIHLOJE{OCCvaX6=	NIHKVYhKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUG5ESVBiY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEOwJI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|MkOxOkc,OjJ6M{KzNVY9N2F-
human PC3 cells	MnLqSpVv[3Srb36gZZN{[Xl?	MlnoOVAh\|ryP	MmjNPEBp	NHf1NndKdmS3Y4Tpc44hd2ZicEKxJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCqdX3hckBRSzNiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjC4JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s	NEHCUYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm5PFQ4Oid-MkK5PVg1PzJ:L3G+
human BT474 cell	NXfIZ\|FFWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NV;QT2xJPzJiaB?=	NUDBZ3RMUW6qaXLpeIlwdiCxZjDoeY1idiCEVES3OEBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JJNx\WO2cn;wbI91d22ndILpZ{BidmGueYPpd-+9lCCLQ{WwQVIxNjdizszNMi=>	NFvlboY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNFAxPSd-MkO0NVAxODV:L3G+
human PC3 cell	MmDuVJJwdGmoZYLheIlwdiCjc4PhfS=>		MmHzO\|IhcA>?	M1TKWWlvcGmkaYTpc44hd2ZiaIXtZY4hWEN\|IHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nlic4DlZ5Rzd3Cqb4TvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTF{LkGg{txONg>?	MkmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ\|NEGwNFA2RC:jPh?=
human PC3 cells	NHLZdXJHfW6ldHnvckBie3OjeR?=		M1;BV\|MxKG2rbh?=	MYDJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFHLWEBxcG:\|cHjvdplt[XSrb36gZZQhe2W{aX7lJFQ4OyCjZoTldkA{OCCvaX7zJIJ6KEWOSWPBMEBKSzVyPUGuN:69VS5?	MmK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ\|NEGwNFA2RC:jPh?=
human MGC803 cells	NYDPS3VMTnWwY4Tpc44h[XO\|YYm=	MVqyOUDPxE1?	MV:0PEBp	M4HR[GNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1ISzhyMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEAzPSC3TTDh[pRmeiB2ODDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDh[pRmeiB2ODDodpMh[nliZnzve{BkgXSxbXX0[ZIhemWuYYTpeoUhfG9iY3;ueJJwdA>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzOUi2PUc,OjRzMUm4Olk9N2F-
mouse RAW264.7 cells	MkTlSpVv[3Srb36gZZN{[Xl?	M2PrNlI2KM7:TR?=	NITJXoczOCCq	M1vyUGlvcGmkaYTpc44hd2ZiUFmzT{9CU1RiaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCrTl;TJJBzd3SnaX6g[ZhxemW\|c3nvckBifCB{NTFOwG0h[W[2ZYKgNlAhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MlOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUm2NVYoRjJ2Mkm5OlE3RC:jPh?=
human A549 cells	MWfQdo9tcW[ncnH0bY9vKGG\|c3H5		MkH0O\|IhcA>?	M3z5UGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD16Mj6zNkDPxE1w	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7M{e4O{c,OjV4OUO3PFc9N2F-
human HuH7 cells	MnrRVJJwdGmoZYLheIlwdiCjc4PhfS=>		NVLBXnk2PzJiaB?=	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjYoPvdoJidmOnIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PjdwMUig{txONg>?	M1LmUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmzO\|g4Lz5{NU[5N\|c5PzxxYU6=
human HCT116 cells	NEHoRndRem:uaX\ldoF1cW:wIHHzd4F6		MknKO\|IhcA>?	NEDDWHBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFje2:{YnHuZ4Uh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME21NU45OiEQvF2u	MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO\|g4RC:jPh?=
human HL60 cells	MmXIVJJwdGmoZYLheIlwdiCjc4PhfS=>		NI\CXow4OiCq	NUnWS\|lRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUG4MlQ{KM7:TT6=	M4D1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmzO\|g4Lz5{NU[5N\|c5PzxxYU6=
Sf9 cells	NX3xTFg{TnWwY4Tpc44h[XO\|YYm=			NGGwcHdKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgbJVu[W5iQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVAhRSB4Lkmg{txONg>?	M4nxZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOUm4N\|UyLz5zMEm5PFM2OTxxYU6=
HeLa cells	M2DLR2Z2dmO2aX;uJIF{e2G7			MmjQTY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NixiSVO1NEA:KDFwNDFOwG0v	M{Xxc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN\|M6Lz5zMkm0NVM{QTxxYU6=
HeLa cells	NXnse4l3TnWwY4Tpc44h[XO\|YYm=			MW\Jcohq[mm2aX;uJI9nKESQQTDk[ZBmdmSnboSgdJJwfGWrbjDrbY5ie2ViaYPvcIF1\WRiZoLvcUBJ\UyjIHPlcIx{NCCLQ{WwJF0hOS53IN88UU4>	MlnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O\|AoRjF3NkW4PFcxRC:jPh?=
Sf21 cells	MYLGeY5kfGmxbjDhd5NigQ>?			NHnKR4VKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy\|LDDJR\|UxKD1iMD65JO69VS5?	M{X4e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4NlY6Lz5zOUe0PFI3QTxxYU6=
Sf21 cells	NIe3PGdHfW6ldHnvckBie3OjeR?=			MojKTY5pcWKrdHnvckBw\iCkb4\pcoUhemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy\|LDDJR\|UxKD1iNzFOwG0v	NYrPeo0{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O\|Q5OjZ7PD;hQi=>
HeLa cells	MoPQSpVv[3Srb36gZZN{[Xl?			NHzFeWdC[3Srdnn0fUBifCCSSUPLJIlvKGi3bXHuJGhmVGFiY3XscJMh[nliRVzJV2EtKEWFNUCgQUAyNjVizszNMi=>	M4q4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEmyN\|I{Lz5{MEC5NlMzOzxxYU6=
Sf21 cells	MU\GeY5kfGmxbjDhd5NigQ>?			MoHMTY5pcWKrdHnvckBw\iCSSUPL[IVtfGFiZYjwdoV{e2WmIHnuJINmdGy\|IHPvMYV5eHKnc4PpcochVi22ZYLtbY5idCCKaYOteIFo\2WmIHj1cYFvKHB6NXGgeZNqdmdiTD3hcJBp[S2yaH;zdIhifGmmeXzpco9{cXSxbDDzeYJ{fHKjdHWgZpkhXEyFIHLhd4VlKHCqb4PwbI9zKGmvYXfpcoctKEmFNUCgQUAxNjV5IN88UU4>	M4HPc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUKwOlMxLz5{MkWyNFY{ODxxYU6=
Sf21 cells	Mn7USpVv[3Srb36gZZN{[Xl?			MkewTY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhWEl\|S3LleIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NEA:KDBwOUeg{txONg>?	NIW3ZWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWyNFY{OCd-MkK1NlA3OzB:L3G+
HL60 cells	NXK2S5dRSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2TsSFMh\GG7cx?=	MlTqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSBzNDFOwG0v	M2n1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
U937 cells	MlzqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVizJIRigXN?	M1rVdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB\|IHThfZMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMUSg{txONg>?	M4nl[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
Jurkat cells	NH\uT5BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYezJIRigXN?	NH71RVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{Bu\WG\|dYLl[EBi\nSncjCzJIRigXNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNlIh\|ryPLh?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
K562 cells	M2rQ[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NY\PXZFqOyCmYYnz	NWDkToFkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCzPEDPxE1w	NFnzN2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U266 cells	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NWizTFhSOyCmYYnz	NUTWfFd5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVNlY3KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTC0OkDPxE1w	NFO1OlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
MDA-MB-231 cells	MYXBcpRqdWmpcnH0c5J6KGG\|c3H5		MXKyOEBpenN?	MUDBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGGpYXnud5QhTUeIIHnu[JVk\WRiY3jlcY91[XirczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMkSgbJJ{KG[xbHzve4VlKGK7IFXHSkBi\GSrdHnvckBnd3JiMz61JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7LDDJR\|UxKD1iMD6zPEDPxE1w	NFrSRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PFI{Pyd-Mke1PVgzOzd:L3G+
MDA-MB-231 cells	M2DSVGFvfGmrbo\hd4l3\SCjc4PhfS=>		MlPNN{42KGi{cx?=	M1vlVGFvfGmrbo\hd4l3\SCjY4Tpeol1gSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhTUeILXnu[JVk\WRiY3XscEBqdn[jc3nvckBi\nSncjCzMlUhcHK\|LDDJR\|UxKD1iMD6zPEDPxE1w	NVnEfIhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwNFk2OjFpPkK4NFA6PTJzPD;hQi=>
HEK293T cells	M4j2SGZ2dmO2aX;uJIF{e2G7		M4W3WVEhcHJ?	MYnJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tj\XSjIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKGi{IHL5JGxENU2VL13TJIFv[Wy7c3nzMEBKSzVyIE2gNE41OiEQvF2u	MlfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
HEK293T cells	MniwSpVv[3Srb36gZZN{[Xl?		MnPPNUBpeg>?	M33ISGlvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2SnbIThJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKEiHS{K5N3Qh[2WubIOgbY5kfWKjdHXkJIZweiBzIHjyJIJ6KEyFLV3TM21UKGGwYXz5d4l{NCCLQ{WwJF0hOS53MzFOwG0v	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
HEK293T cells	NIq1[3ZHfW6ldHnvckBie3OjeR?=		MVexJIhz	Mn\HTY5pcWKrdHnvckBw\iCrbX3vZoltcXqnZDDOMWx[Ojl2MECyJIJm[WRiYnnu[Ilv\yC2bzDQTVNM[WyyaHGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hUEWNMkmzWEBk\WyuczDpcoN2[mG2ZXSg[o9zKDFiaIKgZpkhVENvTWOvUXMh[W6jbInzbZMtKEmFNUCgQUAzNjN5IN88UU4>	NEPvU5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
MDA-MB-231 cells	MYjGeY5kfGmxbjDhd5NigQ>?			NHHHO25KdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJIlvfmG\|aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5\|ODFOwG0v	MoToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MEK0NFEoRjJ6M{CyOFAyRC:jPh?=
MCF7 cells	NEjkbY1HfW6ldHnvckBie3OjeR?=	NYS0XnZ3OTBidV2=	MlPFNUBpeg>?	MYDJcohq[mm2aX;uJI9nKEmJRkHSJJBpd3OyaH;yfYxifGmxbjDheEBVgXJzMU[xJJJme2mmdXWgbY4hcHWvYX6gUWNHPyClZXzsd{BifCBzMDD1UUBi\nSncjCxJIhzKGK7IFjv[YNpe3RiM{OyOVghe3SjaX7pcoch[mG\|ZXSgbY1ufW6xaHnzeI9kcGWvaXPhcEBidmGueYPpdy=>	M4\5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFMxLz5{OEW1O\|Q{ODxxYU6=
SKOV3 cells	MUPGeY5kfGmxbjDhd5NigQ>?	MkjTNlAhfU1?	MV2yOEBpenN?	M{[5Z2lvcGmkaYTpc44hd2ZiQlTOSk1qdmS3Y3XkJIlvfmG\|aX;uJIlvKGi3bXHuJHNMV1Z\|IHPlcIx{KGG2IEKwJJVOKGGodHXyJFI1KGi{czDpckBjgSCvYYTybYdmdCCrbo\hd4lwdiCjc4PhfS=>	NYX4O25PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNlI1QDRpPkK5NVIzPDh2PD;hQi=>
SKOV3 cells	MmHPRY51cW2rZ4LheI9zgSCjc4PhfS=>	MWmyNEB2VQ>?	NU\VOVlmOjRiaILz	NIfBVmxCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCERF7GMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25iYYSgNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KHOlcnH0Z4ghf2:3bnSgbIVidGmwZzDhd5NigQ>?	M3nYUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUKyOFg1Lz5{OUGyNlQ5PDxxYU6=
NB1643 cells	MlvvdWhVWyCjc4PhfS=>			MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50 cells	NULVbphveUiWUzDhd5NigQ>?			NUnJPY1peUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NEi0e5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2 cells	NYOwSJhVeUiWUzDhd5NigQ>?			MnXVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NHTQe\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC cells	MWLxTHRUKGG\|c3H5			NIi5fXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NFPreXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
J774 cells	NVfLOXVSSW62aXnu[oxidW2jdH;yfUBie3OjeR?=		M2\vN\|I1KGi{cx?=	NXLHZ29GSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBLPzd2IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBNWFNvaX7keYNm\CCPQ2CxJIV5eHKnc4Ppc44h[W[2ZYKgNlQhcHK\|IHL5JGVNUVODLDDJR\|UxKD1iMz63JO69VS5?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells	M2P5fWFvfGmrbn\sZY1u[XSxcomgZZN{[Xl?		MX6yOEBpenN?	M2O3e2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhUUx4IHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPS5zIN88UU4>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells	NHKxNHJCdnSraX7mcIFudWG2b4L5JIF{e2G7		NXrtXGFmOjRiaILz	M{LOfmFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36gZYZ1\XJiMkSgbJJ{KGK7IFfybYV{eyCjc4PhfUwhUUN3MDC9JFgvQSEQvF2u	M1GwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells	NWCzWXRETnWwY4Tpc44h[XO\|YYm=	Mo\JNVAhfU1?	M4fJWFQhcHK\|	NIPjTZZKdmirYnn0bY9vKG:oIGDJN2swSWu2IHnuJI1wfXOnIFq3O\|Qh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFzQV{1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44h[XRiU3XyOFc{KGG2IEGwJJVOKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	M3fEb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	E-cadherin / p-Akt / Akt ; beta-catenin / p-GSK3β / Cyclin D1 ; Bcl-xl / Bax / caspase3 / cleaved caspase-3 ; p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin ; pPKB-S473	29731993 25344912 23251002 20649566
Growth inhibition assay	Cell viability	25344912
Immunofluorescence	α-SMA / CD31 ; E-cadherin / beta-catenin ; COX-2 / p-NFκB ; FOXO3a	27671604 29731993 18388194
ELISA	IL-10 / IL-1β / TNFα / IL-6	22208359

In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. ^[2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. ^[3]

Protocol (from reference)

Kinase Assay: ^[4]	kinase assays: PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24^oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research: ^[2]	Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205 Concentrations: 0–50 μM Incubation Time: 0–48 hours Method: 1.0×10⁵ cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37^oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37^oC, after which absorbance at 450 nm is measured with a microplate reader.
Animal Research: ^[3]	Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells Dosages: 0–100 mg/kg Administration: Administered via i.p.

References

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	3mg/mL

Chemical Information

Molecular Weight	307.34
Formula	C₁₉H₁₇NO₃
CAS No.	154447-36-6
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

Download LY294002 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02337309	Terminated	Drug: SF1126	Neuroblastoma	New Approaches to Neuroblastoma Therapy Consortium\|SignalRX Pharmaceuticals Inc.\|University of Southern California	July 9 2015	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

Answer:
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

Question 2:
What is the suggested formulation of this compound for mouse injection(i.p.)?

Answer:
It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):